



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |                          |  |   |
|---|--------------------------|--|---|
| (51) International Patent Classification <sup>7</sup> :<br><b>C12N 15/12, C07K 14/705, 16/28, C12Q 1/68, A61K 38/17, G01N 33/53</b>   |                          | A2   | (11) International Publication Number: <b>WO 00/65054</b>       |
|   |                          |  | (43) International Publication Date: 2 November 2000 (02.11.00) |
| (21) International Application Number: <b>PCT/US00/10884</b>  |                          | (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US).   |   |
| (22) International Filing Date: 20 April 2000 (20.04.00)  |                          |  |   |
| (30) Priority Data:   |                          |  |   |
| 60/130,694  | 23 April 1999 (23.04.99) | US   |   |
| 60/140,580  | 23 June 1999 (23.06.99)  | US   |   |
| (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications  |                          | (74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).   |   |
| US  | 60/130,694 (CIP)         | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |   |
| Filed on  | 23 April 1999 (23.04.99) |  |   |
| US  | 60/140,580 (CIP)         |  |   |
| Filed on  | 23 June 1999 (23.06.99)  |  |   |
| (71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).   |                          |  |   |
| (72) Inventors; and   |                          |  |   |
| (75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118   |                          | Published<br>Without international search report and to be republished upon receipt of that report.  |   |
| (54) Title: HUMAN MEMBRANE-ASSOCIATED PROTEINS  |                          |  |   |
| (57) Abstract   |                          |  |   |
| <p>The invention provides human membrane-associated proteins (HUMAP) and polynucleotides which identify and encode HUMAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HUMAP.</p> |                          |  |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Larvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LJ | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

# PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 11 SEP 2001

WIPO PCT

|  |  |   |
|--|--|---|
| Applicant's or agent's file reference<br>PF-0698 PCT   | FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/116) |   |
| International application No.<br>PCT/US00/10884  | International filing date (day/month/year)<br>20 APRIL 2000  | Priority date (day/month/year)<br>23 APRIL 1999 |
| International Patent Classification (IPC) or national classification and IPC<br>Please See Supplemental Sheet. |  |   |
| Applicant<br>INCYTE GENOMICS, INC  |  |   |

- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 4 sheets.  
☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  
These annexes consist of a total of 0 sheets.
- This report contains indications relating to the following items:
  - ☒ Basis of the report
  - ☐ Priority
  - ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
  - ☐ Lack of unity of invention
  - ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement
  - ☐ Certain documents cited
  - ☐ Certain defects in the international application
  - ☐ Certain observations on the international application

|  |   |
|--|---|
| Date of submission of the demand<br>13 NOVEMBER 2000   | Date of completion of this report<br>27 AUGUST 2001 |
| Name and mailing address of the IPEA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231 | Authorized officer<br>NIRMAL S. BASI                |
| Facsimile No. (703) 305-3230   | Telephone No. (703) 308-0196                        |

**I. Basis of the report****1. With regard to the elements of the international application:\***

- ☒ the international application as originally filed
- ☒ the description:  
pages 1-66, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the claims:  
pages 67-69, as originally filed  
pages NONE, as amended (together with any statement) under Article 19  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the drawings:  
pages NONE, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_
- ☒ the sequence listing part of the description:  
pages 1-28, as originally filed  
pages NONE, filed with the demand  
pages NONE, filed with the letter of \_\_\_\_\_

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**

- ☒ contained in the international application in printed form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☒ The amendments have resulted in the cancellation of:**

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\*Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/10884

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement****1. statement**

Novelty (N)

|        |             |     |
|--------|-------------|-----|
| Claims | <u>1-23</u> | YES |
| Claims | <u>NONE</u> | NO  |

Inventive Step (IS)

|        |             |     |
|--------|-------------|-----|
| Claims | <u>1-23</u> | YES |
| Claims | <u>NONE</u> | NO  |

Industrial Applicability (IA)

|        |             |     |
|--------|-------------|-----|
| Claims | <u>1-23</u> | YES |
| Claims | <u>NONE</u> | NO  |

**2. citations and explanations (Rule 70.7)**

Claims 1-23 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest the protein of SEQ ID NO:1 encoded by the polynucleotide of SEQ ID NO:18, expression vector comprising said polynucleotide, cells containing said vector, antibodies specific to said polypeptide, agonists of said polypeptide, antagonists of said polypeptide, methods of using said polypeptide in treating disease, method of using said polynucleotide in screening assays, and method of using said antibodies/agonists /antagonists.

Claims 1-23 have industrial applicability as set out in PCT Article 33(+), because the polypeptides can be used to produce antibodies, polynucleotides can be used to produce the encoded protein and the antibody, agonist or antagonist can be used in assay methods to detect said polypeptide or in the treatment of diseases associated with decreased or over-expression of functional HUMAO.

\_\_\_\_ NEW CITATIONS \_\_\_\_\_

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/10884

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): G01N 33/50; C12N 15/12, 15/63 and US Cl.: 435/7.1, 4.21, 69.1, 325, 172.3, 252.3; 536/24.1, 23.1; 530/300, 350; 514/2

# PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

**PCT**

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE  
in its capacity as elected Office

|   |   |
|---|---|
| <b>Date of mailing (day/month/year)</b><br>17 April 2001 (17.04.01)           | <b>Applicant's or agent's file reference</b><br>PF-0698 PCT       |
| <b>International application No.</b><br>PCT/US00/10884                        | <b>Priority date (day/month/year)</b><br>23 April 1999 (23.04.99) |
| <b>International filing date (day/month/year)</b><br>20 April 2000 (20.04.00) | <b>Applicant</b><br>HILLMAN, Jennifer, L. et al                   |

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
13 November 2000 (13.11.00)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

**NOT AVAILABLE COPY**

|   |   |
|---|---|
| The International Bureau of WIPO<br>34, chemin des Colombettes<br>1211 Geneva 20, Switzerland<br><br>Facsimile No.: (41-22) 740.14.35 | <b>Authorized officer</b><br><p style="text-align: center;">R. Forax</p> Telephone No.: (41-22) 338.83.38 |
|---|---|

## PCT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

|   |   |  |
|---|---|--|
| Applicant's or agent's file reference<br><b>PF-0698 PCT</b> | <b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below. |  |
| International application No.<br><b>PCT/US 00/ 10884</b>    | International filing date (day/month/year)<br><b>20/04/2000</b>   | (Earliest) Priority Date (day/month/year)<br><b>23/04/1999</b> |
| Applicant<br><b>INCYTE GENOMICS, INC. et al.</b>            |   |  |

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☐ it is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

## 4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

## 5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

## 6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/10884

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 16, 19 and 22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
1-23 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: 1-23, all partially

Polypeptide according to seq.ID.1 or having 90% homology thereto, biologically active and immunogenic fragments thereof, polynucleotide encoding it (e.g. seq.ID.18) or fragments thereof comprising at least 60 contiguous nucleotides, vector comprising said polynucleotide, host transformed with said vector and its use for producing said polypeptide, antibody against said polypeptide, method for detecting said polynucleotide through hybridization, method for identifying an (ant)agonist or a compound that alters the expression of said polypeptide, and a pharmaceutical composition of said polypeptide or said (ant)agonist.

2. Claims: Inventions 2-17: claims 1-23, all partially

Subject matter analogous to that defined above under invention 1, but limited to the respective protein sequences 2-17 and the nucleic acids encoding them, represented by sequences 19-34, whereby invention 2 is limited to seq.ID's 2 and 19, invention 3 is limited to seq.ID's 3 and 20,...., and invention 17 is limited to seq.ID's 17 and 34.

For the sake of conciseness, the first subject matter is explicitly defined, the other subject matters are defined by analogy thereto.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/10884

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K16/28 C12Q1/68 A61K38/17  
G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, STRAND

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | <p>DATABASE EMBL - EMBEST_HUM13 [Online]<br/>Entry HS1271395, Acc.no. AA480075,<br/>23 June 1997 (1997-06-23)<br/>HILLIER, L. ET AL.: "zv42b06.r1 Soares<br/>ovary tumor NbHOT Homo sapiens cDNA clone<br/>IMAGE:756275 5', mRNA sequence."<br/>XP002146174<br/>the whole document</p> | 10-14                 |
| X          | <p>DATABASE EMBL - EMBEST_HUM13 [Online]<br/>Entry HS1227891, Acc.no. AA427548,<br/>25 May 1997 (1997-05-25)<br/>HILLIER, L. ET AL.: "zw22d08.s1 Soares<br/>ovary tumor NbHOT Homo sapiens cDNA clone<br/>IMAGE:770031 3', mRNA sequence."<br/>XP002146175<br/>the whole document</p>  | 10-14                 |

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 August 2000

Date of mailing of the international search report

04 12 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/10884

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 16, 19 and 22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
1-23 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: 1-23, all partially

Polypeptide according to seq.ID.1 or having 90% homology thereto, biologically active and immunogenic fragments thereof, polynucleotide encoding it (e.g. seq.ID.18) or fragments thereof comprising at least 60 contiguous nucleotides, vector comprising said polynucleotide, host transformed with said vector and its use for producing said polypeptide, antibody against said polypeptide, method for detecting said polynucleotide through hybridization, method for identifying an (ant)agonist or a compound that alters the expression of said polypeptide, and a pharmaceutical composition of said polypeptide or said (ant)agonist.

2. Claims: Inventions 2-17: claims 1-23, all partially

Subject matter analogous to that defined above under invention 1, but limited to the respective protein sequences 2-17 and the nucleic acids encoding them, represented by sequences 19-34, whereby invention 2 is limited to seq.ID's 2 and 19, invention 3 is limited to seq.ID's 3 and 20,...., and invention 17 is limited to seq.ID's 17 and 34.

For the sake of conciseness, the first subject matter is explicitly defined, the other subject matters are defined by analogy thereto.